Dementia, drug delivery and in vitro diagnostics benefit from UK Biomedical Catalyst funding boost
This article was originally published in Clinica
Executive Summary
The Biomedical Catalyst, a £180 million ($288 million) public funds pot launched earlier this year by the UK government as part of an initiative to galvanise growth in the life sciences sector, has pumped £22.9 million into a range of early- and late-stage projects led by SMEs.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.